Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state

Immunomodulating monoclonal antibodies (mAb) can evoke antitumor T-cell responses, which are attenuated by regulatory T cells (Treg) and myeloid-derived suppressor cells (MDSC). Treatment with cyclophosphamide (CP) and gemcitabine (GEM) can mitigate the immunosuppression by Treg and MDSC, respective...

Descripción completa

Detalles Bibliográficos
Autores principales: Tongu, Miki, Harashima, Nanae, Tamada, Koji, Chen, Lieping, Harada, Mamoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317772/
https://www.ncbi.nlm.nih.gov/pubmed/25363339
http://dx.doi.org/10.1111/cas.12568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317772/
https://www.ncbi.nlm.nih.gov/pubmed/25363339
http://dx.doi.org/10.1111/cas.12568

Ejemplares similares